Combined effect of branched-chain amino acids and taurine supplementation on delayed onset muscle soreness and muscle damage in high-intensity eccentric exercise

Table 1 Grouping conditions and characteristics of subjects

	Supply condition		Physiological characteristics before experiment
Group	BCAA	Taurine	Age (years)	Height (cm)	Body W. (kg)	Fat (%)	Muscle W. (kg)	MVC (Nm)	CIR (mm)
*PLCB*	Placebo-1	Placebo-2	22.2 ± 1.1	170.8 ± 1.9	67.5 ± 3.5	18.3 ± 1.9	51.9 ± 1.8	36.5 ± 3.0	257.4 ± 7.6
BA	3.2 g	Placebo-2	22.9 ± 1.1	176.7 ± 3.6	73.5 ± 4.3	20.1 ± 1.7	55.3 ± 2.4	41.9 ± 3.8	267.7 ± 7.9
*TAU*	Placebo-1	2.0 g	22.2 ± 0.8	173.7 ± 2.2	65.5 ± 2.7	17.3 ± 1.3	51.7 ± 1.7	39.1 ± 2.4	251.3 ± 7.4
*COMB*	3.2 g	2.0 g	23.1 ± 1.3	174.5 ± 1.8	61.5 ± 1.6	14.2 ± 1.0	50.0 ± 1.3	35.0 ± 2.6	243.4 ± 6.6

Footnote: Data are expressed as means ± S. E. Abbreviation: PLCB, double-placebo control group; BA, branched-chain amino acids and placebo-2 supplement group; TAU, taurine and placebo-1 supplement group; COMB, combined (taurine and BCAA) supplement group; Placebo-1 and 2, placebo of BCAA and taurine supplementation, respectively (3.2g or 2.0g starch mainly), Body W., body weight; Muscle W., muscle weight; MVC, maximal voluntary strength of isometric contraction; CIR, upper arm circumference.

ISSN: 1550-2783